SIRT1 represses PKC ‐zeta activity via regulating interplay of acetylation and phosphorylation in cardiac hypertrophy

Conclusions and ImplicationsSIRT1 is an endogenous negative regulator for PKC ‐zeta and mediates its activity via regulating the acetylation and phosphorylation in the pathogenesis of cardiac hypertrophy. Targeting SIRT1‐PKC‐zeta signaling axis may suggest a novel therapeutic approach against cardiac hypertrophy.

Source: British Journal of Pharmacology - November 10, 2018 Category: Drugs & Pharmacology Authors: Jingyan Li, Junying Huang, Jing Lu, Zhen Guo, Zhuoming Li, Hui Gao, Panxia Wang, Wenwei Luo, Sidong Cai, Yuehuai Hu, Kaiteng Guo, Luping Wang, Zhenzhen Li, Minghui Wang, Xiaolei Zhang, Peiqing Liu Tags: RESEARCH PAPER Source Type: research